-44%

est. 2Y upside i

HealthcareSeries B

Rank

#1415

Sector

Healthtech, Therapeutic Devices, Oral Care

Est. Liquidity

~3Y

Data Quality

Data: Medium

Proclaim presents a moderate upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (33%)+200%

Proclaim successfully leverages its strong clinical efficacy and expanded dental network to drive significant consumer adoption, capturing substantial market share from traditional oral care methods. Strategic partnerships and new product innovations in 2025 further accelerate growth, pushing revenue significantly higher and justifying a $300M+ valuation, representing a 3x return from the current estimated valuation.

Base (38%)+50%

Proclaim continues its steady growth, expanding its dental practice network and seeing moderate consumer uptake of its Custom-Jet Oral Health System. It maintains its niche as a premium, clinically proven solution but faces ongoing competition from incumbents. This leads to a valuation of approximately $150M, a 1.5x return, within the 2-year horizon.

Bear (30%)-50%

Major incumbents like Philips Sonicare or Waterpik launch competitive personalized oral care solutions, eroding Proclaim's market share and pricing power. Slower-than-expected consumer adoption, despite the price reduction, leads to a flat or down round, with the valuation dropping to $50M. Given the $15M in liquidation preferences, common stock value is significantly impaired, resulting in a 50% loss for employees.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Investors hold $15M in liquidation preferences. In an exit at or below the current estimated $100M valuation, common stock holders would see their returns significantly reduced after the preferences are paid out.

Dilution Risk

high

As a Series B company, Proclaim will likely require at least one to two more significant funding rounds (Series C, D) before an IPO or acquisition, leading to further dilution for common shareholders.

Secondary Liquidity

limited

While platforms like EquityZen list opportunities for pre-IPO shares, an active and broad secondary market for Proclaim's stock does not currently exist.

Questions to Ask at the Interview

Strategic questions based on Proclaim's data — designed to show you've done your homework.

  • 1

    “Given the strong incumbent threat from major players like Philips Sonicare, how is Proclaim planning to differentiate its product roadmap and marketing strategy to maintain its competitive edge and avoid direct feature-for-feature competition?”

  • 2

    “With the price reduction from $799 to $599 at the end of 2024, how is the company balancing increased accessibility and unit sales with maintaining gross margins (~65%) and achieving profitability targets?”

  • 3

    “Considering the 'new capital' raised in February 2025 and the previous plan to raise a Series C in mid-2024, what is the current funding strategy and expected timeline for future fundraising rounds or a potential liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates -44% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.